Market News
Stay updated with the latest market trends, earnings, and economic indicators.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
7 most valued firms' mcap eroded ₹1.25 trn last week, RIL took biggest hit
The combined market valuation of seven of the top-10 most-valued firms eroded by Rs 1.25 lakh crore last week, with Reliance Industries taking the biggest hit, in-line with a bearish trend in equities. Last week, the BSE benchmark Sensex declined 532.4 points, or 0.71 per cent, and the NSE Nifty dipped 181.05 points, or 0.76 per cent. "Persistent FII selling remained the key drag on market sentiment despite supportive developments such as cooling crude oil prices and a recovery in the rupee against the US dollar. Concerns regarding the pace of monsoon advancement also weighed on investor confidence," Santosh Meena, Head of Research at Swastika Investmart Ltd, said. From the top-10 pack, Reliance Industries, Bharti Airtel, Tata Consultancy Services (TCS), Bajaj Finance, Larsen & Toubro, Life Insurance Corporation of India (LIC) and Hindustan Unilever faced erosion from their valuation, while HDFC Bank, ICICI Bank, and State Bank of India were the gainers. The market valuation of ...
Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block deal
Shares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece on Tuesday. Promoter-linked entities offloaded their stake, while domestic mutual funds and foreign institutional investors emerged as key buyers, signalling strong institutional participation. The company also launched semaglutide pre-filled syringes in India.
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?
Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pharma index rebounded from early losses to rise nearly 1%, crossing the 25,000 mark and hitting a fresh 52-week high of 25,043.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.
Sensex slumps 847 pts; Nifty trades below 23,950 mark; VIX rallies 8.40%
The Nifty slipped below the 23,950 mark. Pharma, IT and FNCG shares advanced while all the sectoral indices on the NSE traded in the red.

Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.
Sensex dives 850 pts, Nifty slips below 24,200 amid oil shock and weak global cues
The equity benchmark indices Sensex and Nifty tumbled on Thursday, extending losses for a second straight session. Firm crude oil prices and ongoing geopolitical tensions rattled sentiment. Brent crude surged for the fourth consecutive day to around $103 per barrel amid uncertainty over US-Iran talks and fresh concerns around the Strait of Hormuz. Weak Asian cues and persistent foreign fund outflows deepened the sell-off. The Nifty slipped below the 24,200 mark, dragged by auto, PSU banks and consumer durables stocks, while pharma and healthcare shares saw selective buying. Investors stayed cautious, closely tracking the ongoing Q4 earnings season for further triggers.